Medtronic's stent graft dazzles in postmarketing study; Retinal implant's U.S. launch coming soon;

@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev

@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce

> Medtronic ($MDT) reports a new round of positive postmarketing global data for its Endurant II AAA stent graft system. Item

> Second Sight's new Argus II retinal implant will become available for U.S. patients in several weeks. Story

> The CEO of MedVenture Technology is resigning, a year after Helix Medical bought the maker of minimally invasive surgical devices. Item

> Intelligent Implant Systems gained a 510(k) clearance in the U.S. for its Marauder Cervical-Thoracic Spinal surgical system. Item

Biotech News

@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotech, FiercePharma and FierceMedicalDevices! | Follow @FierceBiotech

@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce

@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce

@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce

> Biotech pioneer in 'gene editing' launches with $43M in VC cash. Story

> Orexigen shares soar as long-delayed weight drug clears PhIII safety hurdle. News

> ARMO emerges from stealth mode, preps study of discarded Merck drug. Article

> Portola shoots for early FDA approval after nabbing 'breakthrough' status. Story

> Cubist surges on positive PhIII antibiotic study. Item

Pharma News

@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma

@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce

@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce

> 2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A. Report

> Who leaked the scary Copaxone numbers? Teva aims to find out. Story

> J&J's newly approved Olysio to rival Merck and Vertex entries in hep C market. Item

CRO News

> Indian CROs leap into U.S. with joint venture. News

> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More

> ResearchDx reaches into India for contract diagnostics work. News

> Covance taps NeoGenomics for cancer trial diagnostics. Article

> Vietnam taps Quintiles to up its stake in global trials. Story

Biotech IT News

> Google begins hiring team to lead Calico. More

> Life sciences IT execs plan business intelligence spending blitz. News

> Lilly, Novartis and Pfizer sign up to improve Story

> Report finds inexcusable failings in government cybersecurity. Piece

> Novartis looks to data management vendors to slash costs. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.